Eli Lilly and Company has announced the availability of Zepbound® (tirzepatide) single-dose vials at significantly reduced prices via its self-pay LillyDirect® channel. The vials, available in 2.5 mg and 5 mg doses, offer a discount of at least 50% compared to the list price of other incretin medications for obesity. This initiative seeks to enhance access for adults with obesity who have on-label prescriptions, particularly for those who are not eligible for savings programs, lack employer coverage, or need self-pay options outside of insurance.
Patrik Jonsson, executive vice president and president of Lilly Cardiometabolic Health and Lilly USA, expressed enthusiasm about the launch, stating that it supports the company’s commitment to increasing availability of Zepbound in the U.S. He noted that clinical trials found the 5 mg maintenance dose led to an average weight loss of 15% after 72 weeks, making it an effective option for many individuals struggling with obesity.
To purchase the vials, patients ensure they have a valid on-label prescription from their healthcare provider. This self-pay pharmacy model eliminates reliance on third-party entities, allowing for more transparent pricing and direct savings for patients. Lilly aims to combat counterfeit medications through this channel, ensuring the integrity of the product.
James Zervos, chief operating officer of Obesity Action Coalition, praised Lilly’s initiative, highlighting the critical need for improved coverage and affordability of obesity treatments. He called for collaboration among policymakers, employers, and insurers to ensure equitable access to necessary care.
The pricing structure for Zepbound is set at $399 for a four-week supply of the 2.5 mg vial and $549 for the 5 mg vial, aligning with the savings program for individuals without coverage. Jonsson emphasized the need for innovative solutions in light of outdated insurance policies that often exclude obesity medications from coverage.
Zepbound is clinically proven to facilitate weight loss when used alongside a reduced-calorie diet and increased physical activity. It works by activating specific hormone receptors that help regulate appetite and food intake. While Zepbound is indicated for adults with obesity or those who are overweight with weight-related health issues, it is not approved for use in individuals under 18 years of age.
Zepbound’s availability in additional dosages and its mode of administration, which includes subcutaneous injections, further enhances its accessibility for patients seeking to manage obesity effectively. The company underscores the importance of ensuring that the treatment is both safe and effective, urging patients to consult their healthcare providers for personalized guidance.